Sequelae of Chronic Thyroiditis
The primary sequela of chronic autoimmune thyroiditis is progressive hypothyroidism requiring lifelong levothyroxine replacement therapy, with treatment initiated when TSH exceeds 10 mIU/L or when overt hypothyroidism develops.
Primary Thyroid Dysfunction Sequelae
The natural progression of chronic thyroiditis follows a predictable pattern 1:
- Initial thyrotoxic phase ("hashitoxicosis"): Release of preformed thyroid hormone from destroyed follicular cells, occurring in approximately 4.5% of patients 2
- Euthyroid compensation phase: Remaining thyroid tissue temporarily maintains normal function
- Subclinical hypothyroidism: TSH elevation (typically 2-10 mIU/L) with normal free T4, affecting approximately 30% of patients 2
- Overt hypothyroidism: The ultimate outcome in approximately 42% of patients, requiring permanent replacement therapy 2
Management Algorithm for Hypothyroidism
Initiate levothyroxine when:
- TSH >10 mIU/L in subclinical hypothyroidism 2
- Any degree of overt hypothyroidism (elevated TSH with low free T4) 3
- Dosing: 1.4-1.8 mcg/kg lean body weight daily 4
Monitor TSH every 4-6 weeks until stable, then annually 2. Adjust levothyroxine in 12.5-25 mcg increments to achieve TSH in normal range.
Reproductive Sequelae
Chronic thyroiditis creates significant reproductive complications even in euthyroid patients 3:
- Infertility and menstrual irregularities: Screen all women with these complaints for thyroid dysfunction
- Recurrent miscarriage: TPO antibody-positive women have 2-4 fold increased miscarriage risk even when euthyroid 4
- Postpartum thyroiditis: Develops in up to 25% of women with type 1 diabetes and chronic thyroiditis 3
Pregnancy Management Protocol
For known hypothyroid patients becoming pregnant 3:
- Increase levothyroxine dose immediately upon pregnancy confirmation
- Target TSH <2.5 mIU/L in first trimester, <3.0 mIU/L in second trimester, <3.5 mIU/L in third trimester
- Monitor TSH and total T4 every 4 weeks through 32 weeks gestation
- Use only levothyroxine (never T3 or combination therapy) as T3 does not cross fetal blood-brain barrier adequately 4
For TPO antibody-positive euthyroid patients: Measure TSH immediately upon pregnancy confirmation and initiate levothyroxine if >2.5 mIU/L 3.
Autoimmune Comorbidity Sequelae
Chronic thyroiditis clusters with other autoimmune conditions:
- Type 1 diabetes: Approximately 10% of diabetic patients develop chronic thyroiditis 3. Screen annually with TSH measurement, especially if goiter develops.
- Rheumatic manifestations: Non-erosive arthritis, polyarthralgia, myalgia, and sicca syndrome occur even in euthyroid patients 5, suggesting autoimmune mechanisms independent of thyroid hormone levels
- Associated autoimmune diseases: Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus may coexist 5
Malignancy Risk Sequelae
Chronic thyroiditis increases cancer risk 4:
- Papillary thyroid cancer: 1.6-fold increased risk
- Thyroid lymphoma: 60-fold increased risk
Surveillance strategy: Monitor for nodule development with ultrasound. Any nodule ≥1 cm or with suspicious features requires FNA biopsy regardless of benign thyroiditis diagnosis 6.
Common Pitfalls to Avoid
Do not assume weight gain is thyroid-related: Overt hypothyroidism rarely causes significant obesity; appetite suppression often offsets metabolic slowing 3. Morbidly obese patients may have elevated TSH without true hypothyroidism 3.
Do not use T3 or combination therapy in pregnancy: Only levothyroxine provides adequate fetal thyroid hormone 4.
Do not delay treatment in subclinical hypothyroidism with TSH >10 mIU/L: This threshold warrants treatment, particularly in young patients or those with positive antibodies 2.
Do not overlook TPO antibody testing in reproductive-age women: Even euthyroid antibody-positive women require pregnancy surveillance and potential treatment 3.
In elderly patients with late-diagnosed severe hypothyroidism: Start levothyroxine at lower doses (25-50 mcg daily) to avoid cardiac complications 2.